ReviewClinical cancer research : an official journal of the American Association for Cancer Research2019
Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 318 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
318 citing papers in PubMed, 487 citations in OpenAlex.
- Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Nature communications · 2023Trial
- Protein Expression Dynamics in Breast Cancer Cells Exposed to Nano-Encapsulated Tarin, the Taro Lectin.Pharmaceutics · 2026Article
- In Situ Vaccination, Low-Dose Targeted Radionuclide Therapy, and Immune Checkpoint Inhibition Eradicate Poorly Immunogenic Metastatic Tumors in Murine Cancer Models.Cancer immunology research · 2026Article
- Intestinal Epithelial MHC-II at the Interface of Microbiota, Immunity, and Inflammation.International journal of molecular sciences · 2026Review
- Myeloid landscape of BRAF-mutant papillary thyroid cancer and thyroiditis.Endocrine-related cancer · 2026Article
- Colorectal cancers with distinct metastatic potential trigger divergent early T cell responses.bioRxiv : the preprint server for biology · 2026Article
- Microbial induction of MHC-II expression in colon cancer cells overcomes immunotherapy resistance and limits metastasis.bioRxiv : the preprint server for biology · 2026Article
- Reimagining Nodal Staging in Colorectal Cancer: Toward a Novel Non-Invasive Imaging Approach.Cancers · 2026Review
- Spatial analyses implicate high stromal tumour-infiltrating CD8Nature communications · 2026Article
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy.NPJ precision oncology · 2026Article
- Review
- Article
- Integrating bulk and single-cell sequencing reveals cellular heterogeneity between lung adenocarcinoma in smokers and never-smokers.Journal of biomedical research · 2026Article
- microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3.Nature communications · 2026Article
- Single-cell insights into cisplatin resistance mechanisms in bladder cancer tumor microenvironment.The Journal of biological chemistry · 2026Article
- Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Identification of immunogenic cell death-related prognostic genes in gastric cancer.Journal of gastrointestinal oncology · 2026Article
- Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancer.Science translational medicine · 2026Article
- Single-cell analysis highlights the significance of malignant cell IFN/MHC-II for immunotherapy response in head and neck squamous cell carcinoma.Cell reports. Medicine · 2026Article
- Tumour immune contexture and immune evasion in sporadic and Lynch syndrome-associated microsatellite unstable colorectal cancers.British journal of cancer · 2026Article
258 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Immunotherapy has emerged as a key pillar of cancer treatment. To build upon the recent successes of immunotherapy, intense research efforts are aimed at a molecular understanding of antitumor immune responses, identification of biomarkers of immunotherapy response and resistance, and novel strategies to circumvent resistance. These studies are revealing new insight into the intricacies of tumor cell recognition by the immune system, in large part through MHCs. Although tumor cells widely express MHC-I, a subset of tumors originating from a variety of tissues also express MHC-II, an antigen-presenting complex traditionally associated with professional antigen-presenting cells. MHC-II is critical for antigen presentation to CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.